Recipharm and CTC Forms New Collaboration
News Jun 18, 2014
CTC Clinical Trial Consultants AB and Recipharm Pharmaceutical Development AB have announced that they have entered into a collaboration.
Together the two companies will offer a complete set of packages for Phase I studies including development and manufacture of clinical trial material. The scope will cover planning, performing and evaluation of the clinical trial.
Maria Lundberg, General Manager Recipharm Pharmaceutical Development AB commented: “I am delighted about this collaboration. CTC has excellent experience in clinical trials and a unique phase I unit at Uppsala University Hospital (Akademiska Sjukhuset). Together we will be able to offer customers faster and more cost-efficient phase I studies. We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies.”
Bengt Dahlström, CEO of CTC Clinical Trial said “I am very pleased that CTC and Recipharm now can offer a joint service which will benefit from the companies longstanding expertise in contract development and manufacturing and early clinical research. This systematic integrated approach will help our clients to shorten project time-lines and at the same time obtain more information on the desirable properties of the drug formulation. Adaptive design is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018